Scientists Discover a Drug That Could Make Resistant Tumors Vulnerable Again

When Cancer Learns to Dodge Treatment

One of oncology's most frustrating realities is that many cancer therapies that work brilliantly at first eventually stop working. As Dr. Weei-Chin Lin, a professor of hematology and oncology at Baylor College of Medicine, explains it, cancer cells can activate alternative biological pathways that allow them to overcome the toxic effects of therapy and keep surviving. It's essentially cancer evolving its way out of a corner — and it happens to patients across a wide range of cancer types. Now, a new experimental drug called CS18 may offer a way to outsmart that adaptation.

CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models. The findings were published in the journal Science Advances, providing early evidence supporting further investigation of CS18 as a possible future cancer treatment.

Hitting Cancer's Master Control Panel

What makes CS18 different from many existing drugs is its target. Rather than blocking a single cancer pathway, researchers went after what they describe as a biological switchboard. That switchboard is topoisomerase IIβ-binding protein 1 — known as TopBP1 — a multifunctional scaffold protein that integrates replication stress signaling with oncogenic networks and is frequently overexpressed in aggressive cancers.

The specific segment of TopBP1 that CS18 targets, called BRCT7/8, interacts with several key regulators of cancer growth, including MIZ1, a suppressor of cancer driver MYC; mutant p53, which can acquire cancer-promoting functions; and PLK1 and CIP2A, proteins that help cancer cells survive and divide. These diverse roles make TopBP1-BRCT7/8 a promising target for intervention. By hitting this one hub, CS18 essentially disrupts multiple cancer-survival systems at once — a strategy designed to make it much harder for tumors to adapt and escape.

To find a compound capable of blocking BRCT7/8, the researchers screened thousands of chemicals using a combination of computer modeling and laboratory experiments. That search identified a compound known as 3B6, which the team then modified and tested in numerous versions until they identified CS18 as the most effective candidate.

Promising Results Across Multiple Cancer Types

The researchers observed CS18's effects across several cancer cell types, including triple-negative breast cancer, ovarian cancer, lung adenocarcinoma, lung squamous cell carcinoma, and acute myeloid leukemia, while the drug was less toxic to non-cancerous cells. That selectivity — targeting cancer cells while leaving healthy cells relatively unharmed — is a critical quality for any drug hoping to advance toward human trials.

Combining CS18 with cancer drugs currently in use, such as PARP inhibitors or osimertinib, killed cancer cells more effectively than either drug alone. In the case of lung cancer cells that were already resistant to osimertinib, adding CS18 restored the cells' sensitivity to the drug, increasing cancer cell death. Animal model experiments also showed a significant reduction of tumor growth with no major weight loss or other signs of toxicity.

What Comes Next

The researchers propose CS18 as a candidate for further development as a drug that could become part of combination treatments to prevent or overcome cancer drug resistance. That framing — as a complement to existing therapies rather than a standalone cure — is significant. The goal isn't to replace current treatments but to make them work longer and for more patients, including those who have already stopped responding.

The research is still in early stages, and a long road of clinical testing lies ahead before CS18 could reach patients. But the science behind it addresses one of oncology's most persistent problems with a genuinely novel approach. Strategies that simultaneously target convergent signaling hubs or exploit pathway interdependencies are considered critical to achieving durable responses and overcoming resistance — and that is precisely what CS18 was designed to do. If further studies hold up, it could represent a meaningful shift in how doctors think about keeping cancer treatments effective over the long term.